Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Resources Pharma OK'd to Raise $2 Billion in Hong Kong IPO

publication date: Sep 9, 2016
China Resources Pharma, China's second largest drugmaker, has been approved to stage its IPO on the Hong Kong Exchange, according to reliable, though not official sources. The offering will raise as much as $2 billion, up from earlier estimates of $1 billion to $1.5 billion. Because Hong Kong requires IPO companies to list at least 25% of their shares, the offering terms imply a valuation of $8 billion for CR Pharma. CR Pharma, a unit of state-owned conglomerate China Holdings, already has two subsidiaries that are listed on China exchanges. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital